Search Results 1851-1860 of 19611 for Hemoglobin

1. Deucravacitinib (BMS-986165) in LPP and FFA - Mayo Clinic

   ... hemoglobin < 10 g/dL (100.0 g/L); total white blood cell count < 3000 cells/μL (< 3.00 x 10^3/μL or < 3.00 billion/L); neutropenia (absolute neutrophil ...

2. RESPONDER-HF Trial - Mayo Clinic

   Anemia with Hemoglobin < 10 g/dl 17. Chronic pulmonary disease requiring continuous home oxygen, OR significant chronic pulmonary disease defined as forced ...

3. Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus - Mayo Clinic

   Hemoglobin < 110 g/L (11 g/dL) for females and < 120 g/L (12 g/dL) for males 9. WBC < LLN 10. Platelet count < 150,000/µL 11. ALP > 2 × ULN 12. Patient ...

4. E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS) - Mayo Clinic

   - Hemoglobin (Hb) >= 9 g/dL without ongoing transfusional support (obtained =< 15 days prior to registration) - Absolute neutrophil count (ANC) >= 1.0 x 10 ...

5. A Study to Evaluate the Safety and Effectiveness of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa Evaluating the Safety and Effectiveness of PF-06650833, PF-06700841, and PF-06826647 in Adults with Moderate-to-Severe Hidradenitis Suppurativa - Mayo Clinic

   Hemoglobin < 9.0 g/dL or hematocrit < 30% (< 0.30 v/v);; Absolute lymphocyte count (ALC) < 1.0 x 109 /L (< 1000/mm^3);; Absolute neutrophil count (ANC) < 1.5 ...

6. Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases - Mayo Clinic

   Hemoglobin ≥ 9 g/dL within 21 days prior to registration. Platelet count ≥ 100,000/ mL within 21 days prior to registration. Bilirubin ≤ 1.5 mg/dL (or ...

7. Study to Evaluate the Safety and Effectiveness of BMS-986036 in Adults with Nonalcoholic Steatophepatitis (NASH) and Stage 3 Liver Fibrosis - Mayo Clinic

   Hemoglobin A1c ≥ 10%;; Fasting TGs > 500 mg/dL;; Estimated Glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 according to the Modification of Diet in ...

8. A Study of the Combination of IMCgp100 with Durvalumab and/or Tremelimumab for Patients with Advanced Cutaneous Melanoma - Mayo Clinic

   Absolute neutrophil count (ANC) < 1.0 x 10^9/L; Absolute lymphocyte count < 0.5 x 10^9/L; Platelet count < 75 x 10^9/L; Hemoglobin (Hgb) < 8 g/dL; Potassium ...

9. Erismodegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma - Mayo Clinic

   Hemoglobin ≥ 9.0 g/dL; Serum total bilirubin ≤ 1.5 x ULN (upper limit of normal); Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 ...

10. Publications - Andrew J. Barkmeier, M.D. - Mayo Clinic

    Beyond Hemoglobin A1c-Hypoglycemia, Glycemic Patterns, and Risk of Diabetic Retinopathy. JAMA Ophthalmol. 2025 Dec 1; 143 (12):997-998. View PubMed; Cai CX ...